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ABSTRACT
CLONING AND EXPRESSION PROFILE OF FLT3
GENE DURING RAT LIVER REGENERATION
Iraz Toprak Aydın
M.S. in Molecular Biology and Genetics
Supervisor: Assist. Prof. Dr. Can Akc¸alı
August 2005, 73 Pages
Liver has a unique capacity to regenerate itself upon exposure to viral infections,
toxic reactions and cancer formation which result in the loss of hepatocyte. Liver
regeneration is a complex phenomenon in which several factors participate during
its onset. Cellular proliferation is one of the important component of this process
and the factors regulate this proliferation has a vital role. FLT3, a well-known
hematopoietic stem cell and hepatic lineage surface marker, takes place in pro-
liferative events of hematopoietic stem cells. However, its contribution to liver
regeneration is not known. Therefore, in this study, we aimed to examine the role
of FLT3 during liver regeneration. First we cloned a partial cDNA of rat homolog
of FLT3 from thymus and examined the tissue specific expressions both in mRNA
and protein level. After performing hepatectomy in rats to induce liver regenera-
tion, expression profile of FLT3 in both mRNA and protein level and its cellular
localization were also investigated during the different stages of liver regeneration
models. Our data showed that FLT3 is expressed in most of the rat tissues and
in liver regeneration. However, its intracellular localization is changed during the
late stages of liver regeneration. Therefore, our results suggest a mechanism in
which FLT3 receptor is activated in the late stages of liver regeneration.
Keywords: liver regeneration, FLT3, oval cells, rat.
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O¨ZET
SIC¸AN FLT3 GENI˙NI˙N KLONLANMASI VE
SIC¸ANLARDA KARACI˙G˘ER REJENERASYONUNDA
FLT3 GENI˙NI˙N I˙FADE PROFI˙LI˙NI˙N I˙NCELENMESI˙
Iraz Toprak Aydın
Moleku¨ler Biyoloji ve Genetik, Yu¨ksek Lisans
Tez Yo¨neticisi: Yard. Doc¸. Dr. Can Akc¸alı
Ag˘ustos 2005, 73 Sayfa
Karacig˘erin viral enfeksiyonlar, toksik reaksiyonlar ve kanser olus¸umu sonucu
meydana gelen hepatosit kaybı kars¸ısında, o¨zel bir rejenerasyon kapasitesi vardr.
Karacig˘er rejenerasyonu, birc¸ok fakto¨ru¨n katılımı ile gerc¸ekles¸en karmas¸ık bir
olaydır. Hu¨cresel proliferasyon bu su¨recin o¨nemli parc¸alarından biri oldug˘undan,
proliferasyonu du¨zenleyen etkenlerin rejenerasyonda o¨nemli bir rolu¨ vardır.
Hematopoetik ko¨k hu¨cre ve hepatik-ko¨kenli hu¨cre is¸aretleyicisi olarak bilinen
FLT3 proteininin hematopoetik ko¨k hu¨crelerde proliferasyonda go¨rev aldıg˘ı kabul
edilmektedir. Ancak karacig˘er rejenerasyonunda katkısı bilinmemektedir. Bu
yu¨zden, bu c¸alıs¸mada FLT3’u¨n karacig˘er rejenerasyonundaki rolu¨nu¨ aras¸tırmayı
amac¸ladık. O¨ncelikle sıc¸an timusundan FLT3 homolog˘unun kısmi cDNAsını klon-
layarak FLT3’n deg˘is¸ik dokularda ifadesini mRNA ve protein du¨zeyinde inceledik.
Sıc¸anlarda kısmi karacig˘er c¸ıkarılması ile olus¸turdug˘umuz karacig˘er rejenerasyon
modellerinin deg˘is¸ik as¸amalarında FLT3’u¨n mRNA ve protein du¨zeyinde ifade
profilini ve hu¨cresel lokalizasyonunu aras¸tırdık. Elde ettig˘imiz veriler FLT3’u¨n
birc¸ok sıc¸an dokusunda ve karacig˘er rejenerasyonu su¨recinde ifade edildig˘ini
go¨stermektedir. Bununla birlikte rejenerasyonun ileri as¸amalarında, FLT3’u¨n
hu¨cre ic¸i lokalizasyonunda bir farklılık oldug˘unu saptadık. Sonuc¸larımız, FLT3
resepto¨ru¨nu¨n karacig˘er rejenerasyonun ileri as¸amalarında aktif hale geldig˘ini
du¨s¸u¨ndu¨rtmektedir.
Anahtar so¨zcu¨kler : karacig˘er rejenerasyonu, FLT3, oval hu¨creler, sıc¸an.
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Chapter 1
Introduction
1.1 Liver
The liver is the largest mass of glandular tissue in mammalian body. It is
located in the upper right quadrant of the abdominal cavity. It receives a supply
of arterial blood from hepatic arteries, and from veins of the digestive tube,
pancreas and spleen via the hepatic portal vein. Thus, the liver stands directly in
the pathway of blood vessels that bring substances absorbed from the digestive
tube. This position gives the liver the first chance to metabolize these substances.
It also makes it the first organ to be exposed to toxic compounds that have been
ingested. (Ross et al, 1989)
The liver serves several metabolic functions. Some of these functions are:
(Simpkins and Williams, 1998; Carola et al, 1992)
• formation of urea from amino acids
• manufacture of blood proteins
• formation of erythrocytes during fetal life
• synthesis of the blood-clotting agent fibrinogen
1
• detoxification of many poisons
• synthesis of bile and bile salts for emulsification of fats in the small intestine.
1.1.1 Origin of Mammalian Liver
At the 12-25 somite stage, the liver emerges from the definitive gut endoderm
first as a thickening of the ventral endodermal epithelium and then as a bud of
cells that proliferate and migrate into the surrounding septum transversum mes-
enchyme (Figure 1.1 A, B). The nascent hepatocytes surround spaces within the
septum transversum mesenchyme and the entire domain becomes delineated or
encapsulated as the liver bud grows rapidly into an organ (Figure 1.1 C). The gen-
eral architecture of the liver is laid down at this point (Zaret, 2000; Gilbert, 2003).
Figure 1.1: Overview of Early Liver Development (Zaret, 2000)
During fetal life, the liver is the main site of hematopoiesis and up to 60%
of the liver mass consists of blood cells (Paul et al, 1969). During the perinatal
period, a large number of metabolic enzymes are induced within the hepatocytes
as the hematopoietic cells migrate elsewhere and the liver prepares to control
metabolite and serum protein levels in the blood, store glycogen, and detoxify
(Zaret, 2000).
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1.1.2 Organization of Mammalian Liver
Figure 1.2: The Histological Structure of the Liver Lobule (Ross et al, 1989)
The liver is divided into four lobes. The site where the portal vein, hepatic
artery, bile duct, nerves, and lymphatic vessels enter/leave the liver is called
port hepatis. The portal vein, hepatic artery, and bile duct course together as
a triad, called portal triad, through the stromal ramifications of the liver. The
main cell types resident in the liver are hepatocytes, bile duct epithelium, stellate
cells, Kupffer cells, vascular endothelium, fibroblasts, and leukocytes (Guyton
and Hall, 1996; Lanza et al, 2004; Ross et al, 1989).
The structural and functional unit of the liver is the liver lobule (Figure 1.2).
The central structure of the lobule, traversing its long axis, is the central vein.
Plates of hepatocytes radiate from central vein to the perimeter of the lobule.
The plates are one cell thick and are separated by the hepatic sinusoids, which
are also radially arranged about the central vein. The angular space that contains
the portal triad and the surrounding connective tissue is called the portal canal.
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This canal is bordered by the outer most hepatocytes of the lobule (Guyton and
Hall, 1996; Lanza et al, 2004; Ross et al, 1989).
Bile secreted by hepatocytes is collected in bile ducts, lined by duct epithelial
cells. The canal of Hering is the connection between the bile canaliculi and the
bile ducts at the interface between the lobule and the portal triad (Guyton and
Hall, 1996; Lanza et al, 2004; Ross et al, 1989).
1.2 Liver Regeneration
Liver not only provides means for the body, but also has a great capacity to
regenerate upon harmful conditions with a process known as liver regeneration
as illustrated by the ancient Greek legend of Prometheus. In experimental condi-
tions, it has been shown that animals can survive surgical removal of up to 75%
of the total liver mass (Bucher and Swaffield, 1964).
There are three separate mechanisms for liver regeneration (Grompe and Fine-
gold, 2001):
1. normal tissue turnover
2. hepatocyte-driven regeneration after liver injury
3. progenitor-dependent regeneration after liver injury
1.2.1 Liver Regeneration During Normal Tissue Turnover
The average life span of adult mammalian hepatocytes has been estimated to
be ∼200-300 days. One of the models regarding normal liver turnover was called
the streaming liver. According to this model, normal liver turnover is similar
to regeneration in the intestine. In this model, young hepatocytes born in the
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portal zone migrate toward the central vein. The gene expression patterns of the
hepatocytes, that were located at different zones of the liver, were different. This
phenomenon was explained by the aging process during the migration, which
represented a typical lineage progression. It is also explained that the ploidy
and size of hepatocytes depend on their location within the lobule (Zajicek et
al, 1985, Arber et al, 1988). Central hepatocytes tend to be larger and more
polyploid than periportal hepatocytes. However, other studies provided strong
evidence against the streaming liver model. First, it was shown that the difference
in gene expression pattern in hepatocytes was dependent on the direction of
blood flow (Thurman and Kauffman, 1985). If blood flow was reversed such
that portal blood entered the lobule through the central vein and exited via
the portal vein, the pattern inverted. Therefore, the lobular zonation is best
explained by metabolite-induced gene regulation, not lineage progression. Second,
retroviral marking studies provide evidence against any hepatocyte migration
during normal turnover (Bralet et al, 1994; Kennedy et al, 1995). Retrovirally
marked hepatocytes formed small clones that remained largely coherent and were
equally distributed in all zones of the liver. These results were confirmed in studies
utilizing the mosaic pattern of X-inactivation in female mice to analyze patterns
of hepatocyte growth (Shiojiri et al, 1997, 2000). Thus, current evidence suggests
that normal liver turnover in adult animals is mediated primarily by in situ cell
division of hepatocytes themselves and not stem cells (Ponder, 1996).
1.2.2 Regeneration After Partial Hepatectomy (PH)
During PH, specific lobes of liver are removed intact without damage to the
lobes left behind. The residual lobes grow to compensate for the mass of the
resected lobes, although the removed lobes do not grow back. The process is
completed within one week. There is no evidence for involvement or requirement
of stem cells during this process. Thymidine labeling studies show that virtually
all hepatocytes in the remaining liver divide once or twice to restore the original
cell number within 3-4 days (Bucher and Swaffield, 1964).
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As shown in figure 1.3 the earliest hepatocytes are seen 24 hours after PH.
There is zonal variation depending on how much tissue is removed. When only
15% of the liver is surgically removed, periportal hepatocytes divide preferentially
where as cell division is seen equally in all zones of liver after 75% PH. Following
the hepatocytes, other hepatic cell types also undergo a wave of mitosis, thereby
restoring the original number of cells within 7 days (Bucher and Swaffield, 1964;
Michalopoulus and DeFrances, 1997).
Figure 1.3: Time Course of Liver Regeneration (Michalopoulus and DeFrances,
1997)
1.2.2.1 Factors Involved in Regeneration After PH
Several factors are involved in induction of hepatocyte cell division. HGF is a
primary mitogen for hepatocytes and is responsible for the early events after PH.
The earliest event that takes place within one minute after PH, is a large increase
in the blood level of HGF (Lindroos et al, 1991). It is thought that PH causes
remodeling of extracellular matrix in the liver and release of HGF stored there.
HGF then binds to its receptor c-met and activates a signal transduction pathway
leading to re-entry of hepatocytes into the cell cycle (Bottaro et al, 1991).
Other cytokine-receptor interactions are also important in the cascade result-
ing in mitosis. Known factors are IL-6, TNFα, TGFα, and EGF. Deficiency
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of IL-6 and TNFα in mice caused delayed regeneration after PH (Cressman et
al, 1996; Taub, 1996; Yamada et al, 1997; Yamada and Fausto, 1998). EGF is
a primary mitogen for hepatocytes in tissue culture (Michalopoulos et al, 1984;
Lindroos et al, 1991), but its role in liver regeneration in vivo is not clear since
EGF levels increase only a little after PH (Noguchi et al, 1991). In contrast, it is
shown that, TGFα mRNA and protein levels show an important increase within
hours after PH (Mead and Fausto, 1989), and TGFα overexpression can drive
hepatocyte replication in vivo.
Non-peptide hormones also have an important role in the regeneration after
liver injury. Triiodothyronine (Short et al, 1980) and norepinephrine (Cruise et al,
1988; Cruise, 1991) can stimulate hepatocyte replication in vivo. The relationship
of these factors with progenitor-dependent liver regeneration or engraftment as
well as expansion of liver stem cells, is not known (Grompe and Finegold, 2001).
The mechanisms by which hepatocyte cell division and liver regeneration cease
after the appropriate liver mass has been restored is not clearly known. In particu-
lar, the exogenous signals (endocrine, paracrine, or autocrine) involved in sensing
the overall liver cell mass and negatively regulating its size are not known. Some
studies suggests that TGFβ1 may be important in terminating liver regeneration
(Jirtle et al, 1991). Some endogenous signals are known to participate in the neg-
ative regulation of hepatocyte growth. They include general tumor suppressor
genes. Mice lacking p53 or the p53-inducible cell cycle regulatory protein p21
have been shown to have continuous hepatocyte turnover (Wu et al, 1996; Yin
et al, 1998). Some other hepatocyte-specific transcription factors, like C/EBPα,
are also known to play a role in liver regeneration (Wang et al. 1995; Timchenko
et al. 1996).
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1.2.3 Progenitor Cell-Dependent Liver Regeneration
When liver damage is so severe that hepatocytes are largely killed or that
their proliferation is prevented by exposure to hepatotoxins or carcinogens, liver
progenitor cells with a high nuclear/cytoplasmic ratio, appear in the periportal
areas of liver lobules. These small-cells proliferate extensively, and migrate into
the lobule. These cells, which then become differentiated hepatocytes, are called
oval cells because of their initial morphology (Shinozuka et al, 1978). Oval cells
are thought to have the ability to proliferate clonogenically and a bipotential ca-
pacity to differentiate into both hepatocytes and bile duct cells and have lineage
options similar to those displayed by hepatoblasts in early stages of liver develop-
ment (Vessey and de la Hall, 2001; Kruglov et al, 2002; Sirica et al, 1990; Sirica,
1995).
The oval cells initially appear next to biliary ductules and then some migrate
into the hepatic parenchyma. It has recently been shown that mesenchymal stem
cells can differentiate into hepatocytes passing through oval cell stage (Hong et
al, 2005). Oval cell precursors located in the canal of Hering represent likely
candidates for liver-repopulating stem cells, and can be considered a facultative
liver stem cell (Fausto et al, 1993; Theise et al, 1999). It also has been shown that
oval cells first change into basophilic small hepatocytes and then differentiate into
mature hepatocytes (Mitaka, 2001).
Oval cell proliferation represents progenitor cell-dependent liver regeneration.
In progenitor-dependent liver regeneration, the hepatocytes themselves cannot
divide normally. Thus, progenitor-dependent liver regeneration is utilized when
parenchymal hepatocytes are severely damaged on a chronic basis and unable
to regenerate efficiently (Fausto et al, 1993; Theise et al, 1999). Progenitor-cell
dependent liver regeneration can be triggered by different methods (Table 1.1).
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Chemical/Manipulation Reference
AAF Teebor and Becker, 1971
DEN Schwarze et al, 1984
DEN + AAF + PH Solt et al, 1977
AAF + PH Evarts et al, 1990
Choline-deficient diet + DL-ethionine Shinozuka et al, 1978
D-Galactosamine + PH Lemire et al, 1991
Lasiocarpine + PH Laconi et al, 1995
Retrorsine +PH Laconi et al, 1998; Gordon et al, 2000
Table 1.1: Induction of Progenitor-Dependent Liver Regeneration in Rat (Grompe
and Finegold, 2001)
To induce oval cells in the rat liver, the combination of 2-acetylaminofluorene
(AAF) treatment and PH is often used. AAF is metabolized to its cytotoxic and
mitoinhibitory N-hydroxy derivative molecule by the phase I metabolic enzymes,
which are strongly expressed specifically in adult hepatocytes but relatively low
expressed in biliary cells and oval cells (Alison et al, 1998). The continuous
administration of a low concentration of AAF suppress the proliferation of he-
patocytes and at the middle point of the treatment the animals are subjected to
a massive loss of hepatocytes by PH. When the hepatocytes do not respond to
growth signals, this results in the rapid growth of oval cells (Mitaka, 2001).
Oval cells express both hepatic markers and hematopoietic stem cell markers
such as albumin, AFP, Thy-1, FLT3, c-KIT, CK-18, and CK-19 (Grompe and
Finegold, 2001).
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1.3 FLT3: An Oval Cell Marker
The FLT3 (FLK2, STK-1 ) gene encodes a membrane bound RTK (Stirewalt
and Radich, 2003). The mouse FLT3 gene was cloned by two independent groups
in 1991 (Matthews et al, 1991; Rosnet et al, 1991). The human FLT3 gene was,
cloned in 1993 (Rosnet et al, 1993) whereas rat homolog of FLT3 cDNA has not
been cloned.
1.3.1 Structure of FLT3
FLT3 encodes an RTK of 993 amino acids in length that belongs to the RTK
subclass III family. FLT3 receptor is a membrane-bound receptor (Figure 1.4)
with five immunoglobulin-like extracellular domains, a transmembrane domain,
a juxtamembrane domain and two intracellular TKDs linked by a kinase-insert
domain (Agnes et al 1994; Stirewalt and Radich, 2003).
Figure 1.4: Structure of FLT3 Receptor (Markovic et al, 2005)
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1.3.2 Activation of FLT3
Figure 1.5: Activation of FLT3 Receptor (Stirewalt and Radich, 2003)
Unstimulated FLT3 receptors are in monomeric form in the plasma membrane
(Figure 1.5). In this inactive state, the conformation of the receptor might re-
sult in steric inhibition of dimerization and exposure of phosphoryl acceptor sites
in the TKD by the juxtamembrane domain (Stirewalt and Radich, 2003). Af-
ter stimulation with the ligand, FLT3L, membrane-bound FLT3 quickly changes
conformation, and forms a homodimer and exposes phosphoryl acceptor sites in
TKD (Turner et al, 1996). Dimerization stabilizes this conformational change
which further enhances activation of the receptor (Weiss and Schlessinger, 1998).
Phosphorylation of FLT3 occurs within 5-15 minutes after FLT3L binding.
The FLT3L-FLT3-phosphate complex is then rapidly internalized, starting within
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5 minutes of stimulation and reaching a maximum after 15 minutes. Degraded
byproducts of ligand-receptor complex are seen as early as 20 minutes after stim-
ulation (Turner et al, 1996).
The entire process of activation, internalization and degradation of FLT3 oc-
curs rapidly in cells. The rate of FLT3 production, the speed of degradation of
the activated FLT3L-FLT3 complex, and the downstream effects of activation
probably participate in a complex feedback loop that regulates normal receptor
activity (Stirewalt and Radich, 2003).
1.3.3 The FLT3 Signal Transduction Pathway
Binding of FLT3L to FLT3 triggers the PI3K and RAS pathways (Figure 1.6),
which lead to increased cell proliferation and the inhibition of apoptosis. PI3K
activity is regulated through various interactions between FLT3, SHCs and one
or more other proteins, such as SHIP, SHP2, CBL and GAB2. Activated PI3K
stimulates downstream proteins such as PDK1, PKB (AKT) and mTOR, which
initiate the transcription and translation of crucial regulatory genes through the
activation of p70 S6K and the inhibition of eukaryotic initiation factor 4E-BP1.
In addition, PI3K activation blocks apoptosis through phosphorylation of the
pro-apoptotic BCL2-family protein BAD. Activated FLT3 also associates with
GRB2 through SHC, so activating RAS. RAS activation stimulates downstream
effectors such as RAF, MEKs, ERK, and the 90-kDa ribosomal protein S6 kinase.
These downstream effectors activate CREB, ELK and STATs, which lead to the
transcription of genes involved in proliferation. Both pathways probably also
interact with many other antiapoptotic and cell-cycle proteins, such as WAF1,
KIP1 and BRCA1 (Stirewalt and Radich, 2003).
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Figure 1.6: The FLT3 Signaling Cascade (Stirewalt and Radich, 2003)
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Chapter 2
Aim of the Study
2.1 Aim
Liver responds to certain toxic viral agents or to any condition that results in
the loss of hepatocytes by undergoing regeneration. One of the specific feature
of regenerating liver is an induction in the oval cell population, characterized by
the expression of FLT3 among with other factors.
FLT3 is a well-known hematopoietic stem cell marker that plays a role in
proliferative events. Recent studies support that FLT3 also is a hepatic lineage
surface marker (Hong et al, 2005). Its existence in oval cells further support its
crucial role in hepatocyte development. However, the expression pattern of FLT3
during liver regeneration has not been investigated.
In this study our aim was, first to clone and monitor the tissue specific ex-
pression of rat homolog of FLT3 gene. We also aimed to show the changes
in the expression of FLT3 in both mRNA and protein level, in two models of
liver regeneration, namely hepatocyte-driven liver regeneration and progenitor
cell-dependent liver regeneration.
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2.2 Strategy
In order to achieve the cloning of rat homolog of FLT3 gene, we decided to
amplify the coding region of the gene in three overlapping fragments. For the
amplification of fragments, total cDNA from rat thymus was used as template.
After cloning, we investigated the pattern of FLT3 expression at both mRNA
and protein level in different rat tissues.
Two types of liver regeneration; regeneration after PH and progenitor cell-
dependent liver regeneration, were used as models in this study. For the first
model, PH and SH operations were performed. For the second model, progenitor
cell-dependent regeneration was induced by the administration of AAF followed
by PH or SH operations.
Liver samples were collected from rats at certain times throughout the course
of regeneration. FLT3 expression at both mRNA and protein level was measured
for all groups. Expression at mRNA level was detected by semi-quantitative PCR
and real-time PCR. Protein expression was detected by western blotting. The
localization of FLT3 protein was observed by IHC.
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Chapter 3
Materials and Methods
3.1 Animals
Male, 9-weeks old and 200-300 grams Sprague-Dawley rats were used. They
were housed under controlled environmental conditions (22◦C) with a 12-hour
light and 12 hour dark cycle in the animal holding facility of the Department of
Molecular Biology and Genetics at the Bilkent University, Turkey. The animals
were permitted unlimited access to food and water at all times.
3.2 Solutions and Buffers
PBS
Stock solution (10XPBS) was prepared by dissolving 80g NaCl, 2g KCl, 11.5g
Na2HPO4.7H2O, and 2g KH2PO4 in 1lt ddH2O. Working solution (1XPBS) was
prepared by diluting 10XPBS by ten times. pH was adjusted to 7.4.
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TAE
Stock solution (50XTAE) was prepared by adding 121g Tris, 18.6g EDTA, and
28.55ml glacial acetic acid. The total volume was brought to 500ml with ddH2O.
Working solution (1XTAE) was prepared by diluting 50XTAE by 50 times.
DEPC-Treated Water
1ml DEPC was added to 1lt ddH2O and stirred in a hood for 1 hour. The
water was sterilized and DEPC was inactivated by autoclaving.
LB Medium
10g Tryptone, 10g NaCl and 5g Yeast Extract was dissolved in 1 lt ddH2O.
LB medium was sterilized by autoclaving.
LB-Agar
10g Tryptone, 10g NaCl, 5g Yeast Extract and 15g Bacto-Agar was dissolved
in 1 lt ddH2O. LB agar was sterilized by autoclaving. After the agar was cooled
down to 55-60◦C, desired antibody was added at a working concentration of 1X
and 15-20ml LB-agar was poured into Petri plates aseptically.
Agarose Gel Loading Dye
0.009g BFB, 0.009g XC, 2.8mL ddH2O and 1.2ml 0.5M EDTA was mixed.
The total volume was brought to 15ml by adding glycerol.
1000X Ampicillin
Prepared as a stock solution of 100mg/ml concentration. Sterilized by filtra-
tion. 0.5ml aliqoutes were stored at -20◦C.
1000X Kanamycin
Prepared as a stock solution of 25mg/ml concentration. Sterilized by filtra-
tion. 0.5ml aliqoutes were stored at -20◦C.
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5M NaOH
10g NaOH was dissolved in 50ml ddH2O.
4% PFA
4g PFA was dissolved in 10ml 1XPBS by heating. The solution was kept at
dark and freshly used when it comes 4◦C.
5M NaCl
292.2g NaCl was dissolved in 1lt ddH2O.
10%SDS
100g SDS was dissolved in 1lt ddH2O by stirring.
1M Tris
60.55g Tris was dissolved in ∼300ml ddH2O, 21ml 37% HCl was added. pH
was adjusted to 8.0 with HCl, and the total volume was brought to 500ml by
adding ddH2O.
0.5M EDTA
93.05g EDTA was dissolved in ∼300ml ddH2O by adjusting the pH to 8.0
with NaOH. After pH is adjusted, total volume was brought to 500ml by adding
ddH2O.
30% Acrylamide Mix
145g Acrylamide and 5g bis-acrylamide was dissolved in 500ml. The solution
is filtered for 20 minutes. Acrylamide mix is stored in dark at 4◦C.
SDS-PAGE Running Buffer
5X stock solution was prepared by dissolving 15g Tris, 73.2g Glycine and
5g SDS in 1lt ddH2O. 1X working solution was prepared by diluting the stock
solution 5 times. The stock and working solutions were kept at 4◦C.
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Wet Transfer Buffer
6g Tris, 28.8g Glycine, 1ml 10%SDS and 200ml Methanol was mixed and the
total volume was brought to 1lt by adding ddH2O.
Semi-Dry Transfer Buffer
5.8g Tris, 2.5g Glycine, 0.37g SDS and 200ml Methanol was mixed and the
total volume was brought to 1lt by adding ddH2O.
TBS
10X stock solution was prepared by dissolving 12.19g Tris and 87.76g NaCl
in 1lt ddH2O. 1X working solution was prepared by diluting 10XTBS 10 times.
pH value of 1XTBS was brought to 7.50-7.65 with HCl addition.
TBS-T
1XTBS containing 0.3% Tween-20 was prepared and stored at 4◦C.
Blocking Solution
2.5g dried milk was dissolved in 50ml TBS-T.
Bradford Reagent
100mg CBB was dissolved in 50ml 95%EtOH. 100ml phosphoric acid was
added. Total volume was brought to 1lt with dH2O. The reagent is filtered
through Whatmann No:1 and stored in dark at 4◦C.
Cracking Buffer (2X Protein Loading Buffer)
50 ml Cracking Buffer contaning; 50mM Tris(pH:6.8), 2mM EDTA (pH:8),
1% SDS, 20% Glycerol, 0,02%BFB was prepared. Prior to use 1% β-ME was
added.
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Camiolo Buffer (Protein Extraction Buffer)
0.368g KAc, 0.8765g NaCl, 1ml 0.5M EDTA, 125µl Triton-X100, and 0.871g
L-arginine was mixed and brought to final volume of 50ml with ddH2O. Buffer is
sterilized by filtration.
Coomassie Staining Solution
Staining solution was prepared by dissolving 0.25g CBB in 45ml MeOH, 45ml
ddH2O, 10ml glacial acetic acid.
Coomassie Destaining Solution
Destaining solution containing 20%MeOH and 7% glacial acetic acid was pre-
pared.
SSC
20X stock solution was prepared by dissolving 175.3g NaCl and 88.2 sodium
citrate in 1lt ddH2O. pH value was adjusted to 7.0 with NaOH.
Ponceau-S PVDF Membrane Staining Solution
0.05g Ponceau-S was dissolved in 50ml 5% acetic acid solution.
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3.3 Cloning Studies
3.3.1 Cloning Strategy
The mouse and human FLT3 genes have been previously cloned (Matthews et
al, 1991; Rosnet et al, 1991; Rosnet et al, 1993). In order to clone the rat homol-
ogous of FLT3 cDNA, the sequences of mouse and human genes were compared.
The cDNA sequences of mouse FLT3 (NM 010229), human FLT3 (NM 004119),
and predicted rat FLT3 (XM 221874) were aligned using ClustalW tool (Euro-
pean Bioinformatics Institute).
We aimed to clone the full-length FLT3 cDNA in three overlapping fragments.
The primers were designed for the regions that are conserved among three species.
The locations of the cloning primers is shown in Figure 3.1, and the sequences of
the cloning primers are shown in Table 3.1.
Figure 3.1: Exons of FLT3 and Location of Cloning Primers. We aimed to clone
rat homolog of FLT3 in three overlapping fragments. F1e and R1 primers (shown
in blue) were used for amplifying Part1, F2 and R2 primers (shown in red) were
used for amplifying Part2 and F3 and R3 primers (shown in green) were used for
amplifying Part3. flt3F and flt3R primers, which were previously used to clone
a partial cDNA of rat FLT3 gene (AY094358), were used for RT-PCR in this
study.
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Primer Sequence
F1e 5’-TCT AGA ATG CGG GCG TTG CG-3’
F1 5’-CTG CTT GTT GTT TTG TCA GTA ATG-3’
R1 5’-GGT TGT TCT TAT GAT CGC AAA ATT-3’
F2 5’-ACA GCG TTG GTG ACC ATC CTA-3’
R2 5’-GAA TTG AAT TCC CAT TGA ACC CTG-3’
F3 5’-GTT CAA TGG GAA TTC AAT TCA TTC-3’
R3 5’-TCT AGA CTA ACT TTT CTC TGT GAG-3’
Table 3.1: Sequences of Cloning Primers
3.3.2 Amplification and Purification of FLT3 Fragments
Total cDNA from rat thymus was used as template for PCR amplifications.
The PCR reaction conditions are shown in Table 3.2.
Reaction Mixture 2 µl cDNA from rat thymus
(25 µl reaction volume) 10 pmol forward primer
10 pmol reverse primer
2,3 mM MgCl2 (MBI Fermentas)
1,5 mM dNTP (MBI Fermentas)
2,5 µl 10X PCR Buffer (MBI Fermentas, Ontario, Canada)
1 unit Taq Polymerase (MBI Fermentas, Ontario, Canada)
PCR Reaction
Table 3.2: Reaction Conditions For Cloning of FLT3 Fragments
After amplification, the amplified fragments were electrophoresed on agarose
gel and purified from agarose gel with QIAquick Gel Extraction Kit (QIAGEN,
Hilden, Germany). The DNA fragments were excised from the agarose gel. The
excised parts were weighed. 3 volumes of Buffer QG was added to 1 volume of
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gel, and incubated at 50◦C for 10 minutes. 1 gel volume of isopropanol was added
to the sample and mixed. The sample was applied to the QIAquick column, and
centrifuged for 1 min at full speed. The column was washed by addition of 0.75
ml of Buffer PE, waiting for 5 minutes at room temperature and centrifuging
for 1 min at full speed. The flow-through was discarded and the column was
centrifuged for an additional 1 minute at full speed. The column was placed into
a 1.5ml microcentrifuge tube. To elute the DNA 25-50µl of sterile ddH2O was
applied to the column, waited for 1 minute and centrifuged at full speed for 1
minute. The purified fragments were then sequenced (Iontek, Turkey).
3.3.3 Cloning of Amplified Fragments Into TA Cloning
Vector
The fragments, Part 2 and Part 3, were cloned into pGEM-T Easy (Promega,
Wisconsin, USA) cloning vector. The ligation reaction was prepared by mixing,
10µl 2X Rapid Ligation Buffer (Promega, Wisconsin, USA), 0,5µl pGEM-T Easy
(25 ng), 8,5µl insert DNA and 1µl (3 Weiss units) T4 DNA Ligase (Promega,
Wisconsin, USA). The mixture was incubated at 4◦C for 48 hours.
After the ligation reactions the plasmids carrying the inserts were transformed
into competent E.coli DH5α cells. The competent cells were kindly provided by
Nuri O¨ztu¨rk.
10µl of reaction mixture was added on 50µl of competent cells, and mixed
by finger vortexing, gently. The mixture was incubated on ice for 30 minutes.
Then, transformation mixture was incubated in 42◦C for 90 seconds and on ice
for 2 minutes. After ice incubation, 500µl LB medium was added and mixed
by pipetting. The culture was incubated at 37◦C for one hour. The cells were
precipitated by centrifuging at 12000xg for 5 minutes. 400µl LB was discarded,
and the cells were resuspended in the remaining medium. All the culture in the
microfuge tube was plated to Ampicillin/X-Gal/IPTG plate. The plates were
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incubated in a 37◦C incubator overnight.
The white colonies on the plate were inoculated into 5ml LB containing 1X
Ampicillin and incubated at 37◦C for 8 hours. After 8 hours the plasmids were
isolated by Plasmid Mini Kit (QIAGEN, Hilden, Germany). The orientation of
the inserts were detected by restriction analysis. The E.coli clones that are car-
rying the sense and antisense insert DNA were inoculated into 5ml LB containing
1X Ampicillin, and incubated at 37◦C for 8 hours. After 8 hours, glycerol stocks
of the cultures were prepared by mixing 200µl sterile glycerol with 800µl culture.
The glycerol stocks were stored at -80◦C.
3.4 Liver Regeneration Models
3.4.1 Partial Hepatectomy and Sham Operations Alone
In this study, 9-week old male Sprague-Dawley rats were used. Our partial
hepatectomy operations were performed based on the procedure standarized by
Higgins and Anderson (1931).
3.4.1.1 70% Partial Hepatectomy Operation
The rats were anesthetized with Ketalar (Parke-Davis, Michigan, USA) and
immobilized on the bench. After the sterilization with 70% ethanol, the skins were
cut with a scissor. After removing the subcutaneous structures, the peritoneal
membranes were cut carefully throughout the midline resulting in the opening of
the abdomen. The PH operation is shown in Figure 3.2. Then the ligaments of
the liver that connect the organ to the diaphragm, and the lobes to each other
were cut. The middle lobe, which accounts for the 40% of the total liver mass,
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and the front lobe, which accounts for the 30% of the total liver mass, was cut
after the tying of the branch of vena cava inferior that enters to this lobe with
silk. The color of this lobe immediately became dark after tying, which was due
to the cutting of blood supply to this lobe. Then the lobe was washed in 1X
PBS(DEPC-treated) and then quickly frozen in liquid nitrogen.
Figure 3.2: The Liver Resection Surgery For PH
After removing the lobe, the abdominal cavity of the animal was cleaned care-
fully. The intestines were placed to their original locations. Then the peritonea
and the skin were closed separately by using propilen. After the completion of the
surgery, the animals were placed under a lamp to increase its body temperature
and then put into cages (one animal per cage) with continuous supply of food
and water.
The animals were sacrificed; 30 minutes, 2 hours, 4 hours, 12 hours, 18 hours,
24 hours, 48 hours, 7 days and 14 days after operation. Their livers were taken,
then frozen in liquid nitrogen and stored at -80◦C.
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3.4.1.2 Sham Operations
For the Sham group of animals, all the surgical operations were performed
same as PH operations (Section 3.4.1.1), but the livers were not tied up and
resected.
3.4.2 PH After AAF Treatment
AAF solution (125 mg/ml) was prepared in DMSO. Rats were weighed and 50
mg/kg AAF was administrated to each animal. Before injection desired amount
of AAF solution was resuspended in corn oil to a final volume of 1 ml. AAF was
administrated for 6 days by intraperitoneal injection. On 7th day PH and SH op-
erations were performed as described in Section 3.4.1.1 and 3.4.1.2, respectively.
The animals were sacrificed 2 hours, 12 hours, 18 hours and 24 hours after oper-
ation. Two animals, one form PH group and one from SH group, were injected
with AAF for 6 days after operation and these animals were sacrificed on 7th day.
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3.5 RNA Isolation and Quantification
3.5.1 RNA Isolation
During RNA isolations, all the solutions and materials were treated with
DEPC in order to avoid RNase contamination. The total RNAs were isolated
using Tripure solution (Roche/Boehringer Mannheim, Indiana, USA) according
to the manufacturer’s protocol. 100 mg of tissue samples were homogenized
in 1 ml of Tripure solution by using the homogenizer. The homogenates were
incubated for 5 minutes at room temperature for complete dissociation of the nu-
cleoprotein complexes. Then 0.2 ml of chloroform added and shaken vigorously
for 15 seconds. After incubating them at room temperature for 15 minutes, they
were centrifuged at 12000xg for 40 minutes at 4◦C. Three phase were occurred
after centrifugation. The colorless upper aqueous phases were transferred to new
eppendorf tubes and 1 ml of isopropanol was added on each sample. After mixing
it by inverting the tubes several times, they were incubated at room temperature
for 10 minutes. Then they were centrifuged at 12000xg for 15 minutes at 4◦C
and the supernatant were discarded. The pellets were washed with 1 ml of 75%
ethanol, and then centrifuged at 7500xg for 5 minutes at 4◦C. The supernatants
were discarded and the pellets were air-dried on bench for about 10 minutes. The
RNA pellets were resuspended in appropriate volume of the DEPC-treated water.
The RNAs were stored at -80◦C.
3.5.2 Quantification of RNA
The concentrations of RNA samples were measured via spectrophotometry.
The integrity of the isolated RNA was controlled by agarose gel electrophoresis.
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3.5.2.1 Spectrophotometry
1 µl of each samples were diluted 1:1000 with DEPC-treated ddH2O. Then
the OD measurements were done for 260 and 280 nm wavelengths with the spec-
trophotometer (Beckman, California, USA).
3.5.2.2 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used to control the integrity of the isolated
RNA. 1% agarose gel was prepared with 1X TAE Buffer, and 30 ng/ml ethidium
bromide solution was added for visualization. Samples were prepared by addition
of 1µl Agarose Gel Loading Dye, 3µl RNA sample and 6µl DEPC-treated H2O.
Samples were kept at 65◦C for 10 minutes in order to denature the RNAmolecules.
Agarose gel was run at 100V for 30 minutes and visualized under transilluminator
(Bio-Rad, California, USA). MultiAnalyst (Bio-Rad, California, USA) software
was used to take photographs of the gels.
3.6 cDNA Synthesis
The cDNA samples were synthesized from the total RNA samples with the
RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, Ontario, Canada)
according to the manufacturer’s protocol. 5 µg of RNA was mixed with 1 µl of
oligo(dT) primer and ddH2O in a total volume of 12 µl. They were incubated at
70◦C for 5 minutes and then chilled on ice. Then 4 µl of 5x reaction buffer, 1 µl of
Ribonuclease inhibitor and 2 µl of 10 mM dNTP mix were added and incubated
at 37◦C for 5 minutes. Finally, 1 µl of RevertAid M-MuLV reverse transcriptase
were added and incubated at 42◦C for 60 minutes. The reactions were stopped
by heating at 70◦C for 10 minutes, put into the ice and 20µl of ddH2O was added
to each sample. The cDNAs were stored at -20◦C.
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3.7 RT-PCR
3.7.1 Semi-Quantitative RT-PCR
Semi-quantitative RT-PCR is a suitable method for comparing relative
amount of the used templates between different samples. In order to compare
gene expression levels of samples with each other at RNA level, cyclophilin, a
housekeeping gene, was used as a control of equal loading. Cyclophilin levels
should be equal in cDNAs synthesized from equal amounts of RNA. The cycle
number of RT-PCR reactions were optimized in order to detect the expression lev-
els before saturation of the amplification. Quantification of amplicon intensities
was performed using MultiAnalyst software. The primer sequences and reaction
conditions for CYC and FLT3 are shown in Table 3.3 and 3.4, respectively. The
locations of the primers flt3F and flt3R are shown in Figure 3.3.
CYC Forward Primer 5’-GGG AAG GTG AAA GAA GGC AT-3’
CYC Reverse Primer 5’-GAG AGC AGA GAT TAC AGG GT-3’
Reaction Mixture 2 µl cDNA
(25 µl reaction volume) 10 pmol forward primer
10 pmol reverse primer
1,5 mM MgCl2 (MBI Fermentas, Ontario, Canada)
1,5 mM dNTP (MBI Fermentas, Ontario, Canada)
2,5 µl 10X PCR Buffer (MBI Fermentas, Ontario, Canada)
1 unit Taq Polymerase (MBI Fermentas, Ontario, Canada)
PCR Reaction
Product size 211bp
Table 3.3: Primer Sequences and Reaction Conditions for CYC
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flt3F 5’-TGG TGA CCT GCT CAA CTA CCTA-3’
flt3R 5’-AGT CAC AGA TCT TCA CCA CCTT-3’
Reaction Mixture 2 µl cDNA
(25 µl reaction volume) 5 pmol forward primer
5 pmol reverse primer
1,5 mM MgCl2 (MBI Fermentas, Ontario, Canada)
1,5 mM dNTP (MBI Fermentas, Ontario, Canada)
2,5 µl 10X PCR Buffer (MBI Fermentas, Ontario, Canada)
1 unit Taq Polymerase (MBI Fermentas, Ontario, Canada)
PCR Reaction
Product size 407bp
Table 3.4: Primer Sequences and Reaction Conditions for FLT3
Figure 3.3: Location of FLT3 Primers. flt3F and flt3R primers, which were
previously used to clone a partial cDNA of rat FLT3 gene (AY094358), were used
for RT-PCR in this study.
3.7.2 Real-Time RT-PCR
The primers that are used for semi-quantitative RT-PCR (Section 3.7.1) also
were used for real-time RT-PCR. Before the real-time RT-PCR reactions, the ef-
ficiencies of the primers were tested using a standard dilution series. The reaction
conditions of real-time PCR are shown in Table 3.5.
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The real-time PCR reactions were carried out in iCycler (Bio-Rad, California,
USA). After the amplification steps a melting curve analysis was done.
AAF-treated samples were detected in duplicates, and the readings from each
sample and its internal control (CYC) were used to calculate the gene expres-
sion level. The Ct value of gene expression collected through the amplification
curves was used to analyze the relative expression level by using comperative Ct
(2−∆∆Ct) method (Livak and Schmittgen, 2001). Normal liver was used as a cal-
ibrator for this method. The results of real-time RT-PCR were compared with
the results of semi-quantitative RT-PCR by using CORRELLATION function of
Excel software (Microsoft).
Reaction Mixture for FLT3 1 µl cDNA
(12.5 µl total reaction volume) 5 pmol forward primer
5 pmol reverse primer
6.25 µl iQ SyBr Green Super Mix (Bio-Rad)
Real-Time PCR Reaction of FLT3
Reaction Mixture for CYC 1 µl cDNA
(12.5 µl total reaction volume) 10 pmol forward primer
10 pmol reverse primer
6.25 µl iQ SyBr Green Super Mix (Bio-Rad)
Real-Time PCR Reaction of CYC
Table 3.5: Reaction Conditions For Real-Time RT-PCR
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3.8 Protein Isolation and Quantification
100 mg of tissue samples were homogenized in 1 ml of Camiolo Buffer by using
the homogenizer. The homogenates were centrifuged at 12000xg for 20 minutes
at 4◦C. The supernatant which contains the proteins were taken into a new tube.
The concentration of protein samples were measured with Bradford assay. Ac-
cording to the results of Bradford assay, proteins were diluted to a concentration
of 6µg/µl. The protein samples were stored at -80◦C.
In order to check the equal loading, 12 µg of protein samples were run on
8% SDS polyacrylamide gel. For preparing the protein samples, 2µl protein, 3µl
ddH2O and 5µl Cracking Buffer containing 1% β-ME was mixed and boiled for
5 minutes. 5µl PageRuler Prestained Protein Ladder (MBI Fermentas, Ontario,
Canada) was used as protein molecular weight marker. After electrophoresis,
the gel was stained with Coomassie Staining Solution for 5 minutes and then
destained with Coomassie Destaining Solution overnight. After destaining, the
gel was dried at 60◦C for 45 minutes, and fixed on Whatmann paper.
3.9 Western Blotting
The proteins were separated on 8% SDS polyacrylamide as described in Sec-
tion 3.8. After the electrophoresis, the proteins were transferred to PVDF mem-
brane (Roche, Indiana, USA). The transfer was performed in wet-transfer buffer,
at 14V, at 4◦C overnight. After the transfer is completed the success of the
transfer was controlled by staining the membrane with Ponceau-S PVDF mem-
brane staining solution for 5 minutes, and destaining with water until the protein
bands became visible. After this step the membrane was destained completely
with water, and blotting steps were performed.
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The membrane was blocked with blocking solution for 1 hour at room tem-
perature on an orbital shaker. FLT3 antibody (Santa Cruz, California, USA) was
diluted to a concentration of 0.2 µg/ml in blocking solution, and the membrane
was incubated in antibody solution for 1 hour at room temperature on an or-
bital shaker. Then, the membrane was washed with TBS-T. After washing steps
the secondary antibody, Anti-Rabbit-HRP (Sigma, Montana, USA), was diluted
5000 times in blocking solution, and the membrane was incubated in secondary
antibody solution for 1 hour at room temperature on an orbital shaker. After
secondary antibody step, the membrane was washed with TBS-T.
After the washing step membrane was incubated with ECL Plus Detection
Reagent (Amersham Biosciences, New Jersey, USA) for 5 minutes. The excess
detection reagent was drained off, and the membrane was placed on glass and
covered with SaranWrap. The wrapped glass was placed in a x-ray film cassette.
X-ray films were exposed for 5 seconds, 10 seconds, 30 seconds, 1 minute and 3
minutes. After exposure the films were developed.
3.10 Immunohistochemistry
After the liver tissues were taken from the animals, they were soaked in 1XPBS
and then fixed in 10% neutral phosphate-buffered formalin. After formalin fixa-
tion, the tissues were dehydrated and embedded into paraffin and stored at room
temperature. For immunohistochemistry 7µm sections were taken. The sections
were deparafinized by incubating at 60◦C for 20 minutes and keeping in xylene for
5 minutes. After deparaffinization, tissue sections were rehydrated by immersing
them into 100%, 95%, 80%, 65%, 50%, 40%, and 30% ethanol for 2 minutes each,
respectively, and then the sections were immersed in dH2O for 2 minutes. After
deparaffinization and rehydration steps, in order to quench endogenous peroxi-
dase activity, the tissue sections were incubated in 3% H2O2 for 25 minutes.
After H2O2 step, the sections were washed with 1XPBS and the specimen
were blocked with 2% BSA for 1 hour at room temperature in humid chamber.
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Primary antibody, FLT3 antibody (Santa Cruz, California, USA), was diluted
to 5µg/ml in 1% BSA, and the specimen were covered with primary antibody
solution and incubated for overnight at 4◦C in humid chamber. After primary
antibody incubation, the sections were washed with 1XPBS and incubated with
Biotinylated Link Anti-Mouse & Anti-Rabbit Ig (DakoCytomation, Glostrup,
Denmark) for 15 minutes at room temperature. Then the sections were washed
with 1XPBS and incubated with Streptavidin-HRP (DakoCytomation, Glostrup,
Denmark) for 15 minutes at room temperature, and the sections were washed
with 1XPBS.
After washing step, the specimen were covered with Liquid DAB+ Substrate
(DakoCytomation, Glostrup, Denmark) and incubated for 10-15 seconds and im-
mediately washed with dH2O. After substrate step the specimen were counter-
stained with hematoxylin for 30 seconds, rinsed with dH2O, and washed with
tap water. After the washing step the specimen were mounted using Faramount
Aqueous Mounting Medium (DakoCytomation, Glostrup, Denmark), and cover-
slipped.
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Chapter 4
Results
4.1 Cloning Studies
We aimed to clone the rat homolog of FLT3 cDNA in three overlapping frag-
ments (Part1, Part2, Part3) (Figure 4.1).
Figure 4.1: Location of Cloning Primers. F1e and R1 primers (shown in blue)
were used for amplifying Part1, F2 and R2 primers (shown in red) were used
for amplifying Part2 and F3 and R3 primers (shown in green) were used for
amplifying Part3.
Part1, Part2 and Part3 of rat FLT3 cDNA were amplified from thymus. The
first attempt of amplifying Part1 with primers F1e and R1 was not successful
since the beginning of the coding region was GC rich and we could not man-
age optimization of PCR conditions for this primer set. Then a second forward
primer F1 that recognizes a sequence which is located approximately 35 bases
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after the beginning of the coding region was designed, and Part1 was amplified
with primers F1 and R1 (Figure 4.2).
Figure 4.2: Agarose Gel Electrophoresis of PCR Products Part1, Part2 and Part3.
All the fragments were amplified from thymus cDNA. The sizes of the amplified
fragments were expected. 100bp DNA Ladder Plus (MBI Fermentas) was used as
molecular size marker.
The amplified fragments were sequenced. Combining the sequence analysis
results of Part1, Part2, and Part3, along with a small fragment we previously
cloned (AY94358), we were able to determine a partial cDNA sequence for rat
homolog of FLT3 gene (Figure 4.3).
Obtained partial sequence of rat FLT3 was aligned with mouse FLT3
(NM 010229) and human FLT3 (NM 004119) (Figure 4.4), and aligned with
a predicted rat FLT3 sequence (XM 221874) (Figure 4.5) by BCM Search
Launcher: Multiple Sequence Alignments tool (Baylor College of Medicine). The
partial sequence showed 90% homology with mouse sequence and 81% homology
with human sequence. When the alignment data is considered, we saw that ∼80
bases from the beginning of the coding region were missing from our partial se-
quence in comparison to mouse and human sequences. In the alignment between
rat and predicted rat sequences; we saw that there were gaps in alignment. The
predicted sequence constructed by gene scan was including some regions that did
not correspond to our sequencing results.
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Figure 4.3: Partial Sequence of Rat Homolog of FLT3 cDNA
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Figure 4.4: Comparison of Rat, Mouse (NM 010229) and Human (NM 004119)
FLT3 cDNAs. The regions that are conserved in all three species are shown in
black blocks.
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Figure 4.5: Comparison of Rat and Predicted Rat (XM 221874) FLT3 cDNAs.
The regions that are conserved in all three species are shown in black blocks.
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4.2 Tissue Specific Expression of FLT3
We analyzed the expression of FLT3 in different rat tissues both at mRNA
(Figure 4.6) and protein (Figure 4.7) level. For this purpose, female and male
rats were sacrificed and their tissues were collected. RNA isolation and RT-PCR
were performed as explained in Section 3.5, 3.6, and 3.7. Protein isolation and
Western blotting were performed as explained in Section 3.8 and 3.9.
Our results showed that, although FLT3 expression at mRNA level was seen
in all the tissues, the expression level was not the same (Figure 4.6). In uterus,
spleen, cerebellum and lungs the expression of FLT3 was higher, whereas in brain,
ovary and skeletal muscle FLT3 level remained rather low.
Figure 4.6: The Expression of (A)FLT3 and (B)CYC In Different Rat Tissues.
M: 100bp DNA Ladder Plus (MBI Fermentas, Ontario, Canada), -: the negative
control
In contrast to presence of FLT3 mRNA in heart and kidney (Figure 4.6),
we did not detect any expression at protein level in these tissues (Figure 4.7A,
first two lanes). Furthermore, in all the tissues, except liver, the FLT3 band
corresponded to ∼150-160 kDa, whereas in liver the FLT3 band corresponded to
∼130-140 kDa.
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Figure 4.7: Western Blot of Proteins From Different Rat Tissues. (A) West-
ern blotting of different rat tissue proteins with anti-FLT3 antibody and (B) the
Coomassie staining of SDS-PAGE of same proteins.
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4.3 Semi-Quantitative RT-PCR Results
4.3.1 Expression of FLT3 in SH and PH Groups
The expression of FLT3 at mRNA level in SH and PH groups were analyzed by
semi-quantitative RT-PCR. PH and SH operations were performed as explained
in Section 3.4.1. 30 minutes, 2 hours, 4 hours, 12 hours, 18 hours, 24 hours, 48
hours, 7 days and 14 days after operations, a single rat from PH group and an-
other from SH group were sacrificed and their liver tissues were collected. RNA
isolation, cDNA synthesis and RT-PCR were performed as explained in Section
3.5, 3.6, and 3.7. The PCR products were run on agarose gel (Figure 4.8).
Figure 4.8: Expression of FLT3 in SH and PH Groups. M: 100bp DNA Lad-
der Plus, - : is the negative control, and NL: normal liver sample. (A) FLT3
amplification in SH groups, (B) CYC amplification in SH groups, (C) FLT3 am-
plification in PH groups, and (D) CYC amplification in PH Groups
The quantification results for SH and PH groups are given in Table 4.1. Rel-
ative expression of FLT3 was calculated in comparison to the expression of CYC.
In SH groups a slight but consistent decrease in FLT3 expression over the pe-
riod of regeneration was apperant. In PH groups a similar pattern was observed
but to a greater degree than that observed in SH groups. The expression was
then increased after 18 hours (Figure 4.9).
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NAME FLT3 Density CYC Density Relative Expression
NL 12830,26 13479,02 100,00
SH 2h 10925,66 11362,50 101,02
SH 12h 11543,75 15498,81 78,25
SH 18h 8485,86 14201,79 62,77
SH 24h 11670,72 16323,21 75,11
SH 7d 8651,64 15186,31 59,85
NL 12830,26 13479,02 100,00
PH 2h 8265,38 12358,93 70,26
PH 12h 7429,06 13842,26 56,38
PH 18h 4753,85 14788,10 33,77
PH 24h 6242,74 17483,33 37,51
PH 7d 12017,99 16773,21 75,27
Table 4.1: Quantification of Semi-Quantitative PCR Results for SH and PH
Groups.
Figure 4.9: FLT3 expression in SH and PH Groups
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4.3.2 Expression of FLT3 in AAF-Treated SH and PH
Groups
The expression of FLT3 at mRNA level in AAF-treated SH and PH groups
were analyzed by semi-quantitative RT-PCR. AAF treatment, followed by PH
and SH operations were performed as explained in Section 3.4.2. 2 hours, 12
hours, 18 hours, 24 hours, and 7 days after operations, one rat from PH group
and one rat from SH group were sacrificed and their liver tissues were collected.
RNA isolation and RT-PCR were performed as explained in Section 3.5, 3.6, and
3.7. The PCR products were run on agarose gel (Figure 4.10).
Figure 4.10: Expression of FLT3 in AAF-Treated SH and PH Groups. M: 100bp
DNA Ladder Plus, - : the negative control, NL: normal liver sample, and 0h: liver
sample taken from an AAF-treated animal which is not subjected to PH. (A) FLT3
amplification in AAF-treated SH and PH groups,and (B) CYC amplification in
AAF-treated SH and PH groups.
The quantification results for AAF-treated SH and PH groups are given in
Table 4.2. Relative expression of FLT3 was calculated in comparison to expression
of CYC.
In AAF-treated SH groups, except 24 hours groups there was a slight decrease
in FLT3 mRNA level (Figure 4.11). In AAF-treated PH groups, FLT3 mRNA
level appeared to have decreased starting from 2 hours.
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NAME FLT3 Density CYC Density Relative Expression
NL 4735,19 7227,02 100,00
AAF 0h 10321,30 15286,29 103,05
SH-AAF 2h 8476,85 11795,97 109,68
SH-AAF 12h 9796,30 12124,19 123,32
SH-AAF 18h 11250,93 13402,82 128,12
SH-AAF 24h 6890,74 16808,47 62,57
SH-AAF 7d 11671,30 15207,66 117,13
PH-AAF 2h 9240,74 14517,74 97,15
PH-AAF 12h 7395,37 15881,85 71,07
PH-AAF 18h 9538,89 15984,68 91,08
PH-AAF 24h 6277,78 16212,90 59,10
PH-AAF 7d 7037,96 14235,89 75,45
Table 4.2: Quantification of Semi-Quantitative PCR Results for AAF-Treated SH
and PH Groups
Figure 4.11: FLT3 expression in AAF-Treated SH and PH Groups
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4.4 Real-Time RT-PCR Results
For real-time RT-PCR studies the cDNA samples which were used for semi-
quantitative RT-PCR of SH, PH, AAF-treated SH, and AAF-treated PH groups
were used. The real-time PCR reactions were performed as explained in Section
3.7.2. Efficiency of CYC and FLT3 primers were tested, standard curves were
derived and E values were calculated for both primer sets. Since E values of CYC
and FLT3 were 1,9 and 1,95, respectively, the E values were accepted as 2 for
calculations.
4.4.1 Expression of FLT3 in SH and PH Groups
The Ct values of SH and PH groups (normal liver, 2 hours, 12 hours, 18 hours,
24 hours and 7 days) for both FLT3 and CYC were collected. The Ct values of
the PH groups were normalized according to the difference between the Ct values
of normal liver samples in both groups. By using normalized Ct values, ∆Ct
(∆CtFLT3 −∆CtCY C ) value for each group was calculated. Fold change in expres-
sion of FLT3 was calculated by using 2−(∆Ct−∆CtNL ) formula. For calculation,
∆Ct of normal liver sample was used as calibrator. Table 4.3 and Table 4.4 show
the real-time RT-PCR data and the results of the calculations for SH and PH
groups, respectively. Figure 4.12 and figure 4.13 show the fold changes of FLT3
expression graphics for SH and PH groups, respectively.
Real-time PCR quantifications showed that, FLT3 expression pattern of SH
groups (Figure 4.12) is consistent with semi-quantitative PCR results (Figure
4.9). The correlation value of semi-quantitative RT-PCR and real-time RT PCR-
was 0,99 for SH groups. Also, quantifications of PH groups (Figure 4.13) was
similar with semi-quantitative PCR of PH groups (Figure 4.9). The correlation
value was 0,88 for PH groups.
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NAME FLT3 Ct CYC Ct ∆Ct 2
−(∆Ct−∆CtNL )
NL 22,7 13,3 9,4 1,00
SH 2h 23,2 13,5 9,7 0,81
SH 12h 23,2 13,1 10,1 0,62
SH 18h 24,3 13,8 10,5 0,47
SH 24h 23,3 13,1 10,2 0,57
SH 7d 24,3 13,7 10,6 0,44
Table 4.3: Real-Time RT-PCR Data For SH Groups
Figure 4.12: Fold Change in FLT3 expression in SH Groups
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NAME FLT3 Ct CYC Ct ∆Ct 2
−(∆Ct−∆CtNL )
NL 22,7 13,3 9,4 1,00
PH 2h 22,5 13,9 8,6 1,74
PH 12h 23,8 13,7 10,1 0,62
PH 18h 26,1 13,9 12,2 0,14
PH 24h 23,7 12,3 11,4 0,25
PH 7d 21,7 12,4 9,3 1,07
Table 4.4: Real-Time RT-PCR Data For PH Groups
Figure 4.13: Fold Change in FLT3 expression in PH Groups
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4.4.2 Expression of FLT3 in AAF-Treated SH and PH
Groups
The Ct values of AAF-treated SH and PH groups (normal liver, 0 hour, 2
hours, 12 hours, 18 hours, 24 hours and 7 days) for both FLT3 and CYC were
collected. The Ct values of the AAF-treated PH groups were normalized according
to the difference between the Ct values of normal liver samples and 0 hour samples
in both groups. By using normalized Ct values, ∆Ct (∆CtFLT3 −∆CtCY C ) value
for each group is calculated. Fold change in expression of FLT3 was calculated
by using 2−(∆Ct−∆CtNL ) formula. For calculation, ∆Ct of normal liver sample was
used as calibrator. Table 4.5 and Table 4.6 show the real-time RT-PCR data and
the results of the calculations for AAF-treated SH and PH groups, respectively.
Figure 4.14 and Figure 4.15 show the fold changes of FLT3 expression graphics
for AAF-treated SH and PH groups, respectively.
In AAF-treated SH groups (Figure 4.14), except 24 hours sample, an im-
portant change in FLT3 expression was not seen. Real-time RT-PCR results of
AAF-treated SH groups were consistent with semi-quantitative RT-PCR results.
The correlation value between these groups was 0,95. In AAF-treated PH groups
(Figure 4.15), a great decrease in FLT3 expression was seen in all the groups
after 2 hours. However, the correlation of semi-quantitative RT-PCR results and
real-time RT-PCR results was not as high as previous groups. The correlation
for AAF-treated PH groups was 0,45.
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NAME FLT3 Ct CYC Ct ∆Ct 2
−(∆Ct−∆CtNL )
NL 23,5 16,1 7,4 1,00
AAF 0h 22,6 15,5 7,1 1,23
SH-AAF 2h 23,3 15,2 8,1 0,62
SH-AAF 12h 22,5 15,0 7,5 0,93
SH-AAF 18h 22,4 14,8 7,6 0,90
SH-AAF 24h 24,8 14,9 10,0 0,17
SH-AAF 7d 22,8 15,1 7,7 0,81
Table 4.5: Real-Time RT-PCR Data For AAF-Treated SH Groups
Figure 4.14: Fold Change in FLT3 expression in AAF-Treated SH Groups
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NAME FLT3 Ct CYC Ct ∆Ct 2
−(∆Ct−∆CtNL )
NL 23,6 16,4 7,2 1,00
AAF 0h 22,5 15,2 7,3 0,97
PH-AAF 2h 23,9 15,1 8,8 0,34
PH-AAF 12h 23,6 14,3 9,3 0,23
PH-AAF 18h 23,0 14,1 8,8 0,33
PH-AAF 24h 23,4 14,2 9,1 0,27
PH-AAF 7d 23,0 14,5 8,5 0,42
Table 4.6: Real-Time RT-PCR Data For AAF-Treated PH Groups
Figure 4.15: Fold Change in FLT3 expression in AAF-Treated PH Groups
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4.5 Western Blotting Results
4.5.1 Western Blotting of SH and PH Groups
Protein isolation and Western blotting were performed as explained in Section
3.8 and 3.9. The proteins extracted from SH and PH groups were subjected to
Western Blotting with anti-FLT3 antibody. As equal loading control, the proteins
were run on SDS-PAGE and the gel was stained with Coomassie Brilliant Blue.
FLT3 protein level was similar in all SH groups. However, in PH groups,
FLT3 protein started to increase after 48 hours past operation. (Figure 4.16A).
Figure 4.16: Western Blotting of SH and PH Groups. (A) Western blotting of
different proteins extracted from SH and PH groups with anti-FLT3 antibody and
(B) Coomassie staining of SDS-PAGE of same proteins.
4.5.2 Western Blotting of AAF-Treated SH and PH
Groups
Protein isolation and Western blotting were performed as explained in Section
3.8 and 3.9. The proteins extracted from AAF-treated SH and PH groups were
subjected to Western Blotting with anti-FLT3 antibody. As equal loading control,
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the proteins were run on SDS-PAGE and the gel was stained with Coomassie
Brilliant Blue.
In AAF-treated SH groups, an increase at protein level was observed in 18th
hour and 24th hour. In AAF-treated PH groups, a decrease at protein level was
observed from 18th hour through 7th day (Figure 4.17A).
Figure 4.17: Western Blotting of AAF-Treated SH and PH Groups. (A) Western
blotting of different proteins extracted from AAF-treated SH and PH groups with
anti-FLT3 antibody and (B) Coomassie staining of SDS-PAGE of same proteins.
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4.6 Immunohistochemistry
In Western blotting studies, we observed FLT3 protein in all samples. In order
to examine the location of FLT3 in these groups we performed immunoperoxi-
dase assay on normal liver (NL) and AAF-treated SH and PH groups. IHC is
performed as described in Section 3.10.
We first examined the presence of FLT3 protein in NL (Figure 4.18A), and
AAF-treated liver (Figure 4.18C), and found its expression in both samples. The
negative control (Figure 4.18B) did not reveal any staining.
Figure 4.18: Immunohistochemistry of Normal Liver and AAF-Treated Liver.
(A) is IHC of NL with anti-FLT3 antibody, (B) is negative control of IHC of
AAF-treated liver, and (C) is IHC of AAF-treated liver with anti-FLT3 antibody.
Then we performed IHC to all our PH and SH groups (Figure 4.19). Similar
to normal liver, we found the expression of FLT3 in those groups. Interestingly
the cellular localization of this protein was different among our samples. In all
AAF-treated SH groups and early PH groups (2 hours, 12 hours, and 18 hours),
FLT3 was located on plasma membrane. But in late PH groups (24 hours and 7
days) FLT3 was mainly seen in the cytoplasm (Figure 4.20).
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Figure 4.19: Immunohistochemistry of AAF-Treated SH and PH Groups. (A)-(E)
negative controls of PH groups, (F)-(J) IHC of PH groups, and (K)-(O) IHC of
SH groups.
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Figure 4.20: Comparison of IHC Results of 18 hours and 7 days Groups. The
location of FLT3 protein is shown with black arrows.
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Chapter 5
Discussion
5.1 Discussion
Liver regeneration, first mentioned in legend of Prometheus, is a complex
physiological response that takes place after the loss of hepatocytes caused by
toxic or viral injury or secondary liver resection. During regeneration, series
of reactions take place to survive the organism, and proliferative and apoptotic
mechanisms operate to provide a balance for the survival. Previously, our lab has
shown the involvement of bcl-2 family of genes during liver regeneration (Akcali
et al, 2004). Therefore, in this study we focused on the other aspect of liver
regeneration; mechanisms or participants of the proliferative response.
Recent data revealed that hepatocytes can regenerate or proliferate from three
types of cells. After normal liver tissue renewal or if the liver damage is less
severe, mature hepatocytes respond rapidly to liver injury. On the other hand, in
response to allyl alcohol injury or during hepatocarcinogenesis, exogenous liver
stem cells, which may derive from circulating HSCs or bone marrow stem cells
take part. These are multipotent cells and have very long proliferation potential,
but are rare. Finally, oval cells, which are activated to proliferate when the liver
damage is extensive and chronic, or if proliferation of hepatocytes is inhibited,
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may be the source of new hepatocytes (Zhang et al, 2003). Those cells can be
regarded as bipotential precursors for the two hepatic parenchymal cell lineages;
hepatocytes or cholangiocytes (Sirica, 1995). Canal of Hering is known as the
source of precursors of oval cells. In addition, Hong et al (2005) very recently
showed that bone marrow-derived mesenchymal stem cells have the potential to
differentiate into hepatocyte-like cells passing through oval cell stage. This study
strongly suggests that the progenitors of oval cells may initially come from bone
marrow. Oval cells express specific proteins and FLT3 is considered as one of
these proteins. Therefore, Hong et al ’s data may explain the reason of existence
of a hematopoietic stem cell marker, FLT3, in oval cells; since they share common
progenitors.
FLT3 is a subclass III RTK, which is a well-known hematopoietic stem cell
marker as well as a hepatic lineage surface marker as well (Hong et al, 2005).
Therefore, its existence in oval cells supports its role in hepatocyte development.
Being a RTK it is logical for FLT3 to assign a role during liver regeneration.
However, its expression pattern is not known during liver regeneration. Therefore,
we aimed to investigate the expression profile of FLT3 during different models of
rat liver regeneration.
The first model we used, was regeneration after partial hepatectomy. The sec-
ond model was progenitor cell-dependent liver regeneration which was triggered
with AAF-treatment in combination with PH.
In both models, there was a reduction at mRNA transcript level of FLT3 after
PH (Figures 4.9, 4.11, 4.13, 4.15). In SH groups, the anesthetic we used may have
an effect on the expression profile of liver cells, that may be the reason of the
differences in the FLT3 level in SH groups. The reduction of mRNA transcript
level of FLT3 in PH groups may be related with the massive loss of cells. Except
late AAF-treated PH groups, we did not observe a correlation between Western
blotting results and RT-PCR result which suggests that, transcriptional regula-
tion of FLT3 does not take place during regeneration. Therefore, we focused on
the translational events. When we examined the data regarding the amount of
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FLT3 protein only in the late stages of AAF-treated PH groups there was a corre-
lation between FLT3 protein level and transcript level. Apart from these groups
the protein level was almost equal in all other groups. In order to draw exact
conclusions from RT-PCR and Western blotting data, the experiments should be
repeated and statistical calculations should be done.
On the other hand, our immunohistochemistry studies revealed a different
pattern in the localization of FLT3 protein in different experimental groups (Fig-
ure 4.20). In all AAF-treated SH groups and in early groups of AAF-treated PH
samples (2 hours, 12 hours and 18 hours), FLT3 expression was seen exclusively
on the plasma membrane. Whereas, in later AAF-treated PH groups, especially
in 7 days after PH group, there was a strong cytoplasmic staining.
The data regarding to the cellular difference in the expression of FLT3 during
early and late stages of liver regeneration strongly suggests the activation status
of the receptor. Under normal conditions (normal liver and SH groups), FLT3
resides in the plasma membrane in inactive monomeric form. When liver injury
occurs, the liver undergoes a regeneration process and during this process FLT3
can be activated in order to relay signals for proliferative events. This activation
is followed by internalization of receptors as shown by Turner et al (1996) and
ultimately results in degradation. Therefore, the cytoplasmic staining of FLT3
protein that we observed in late AAF-treated PH groups may be the internalized
FLT3 receptors. This data suggests that, FLT3 is activated during this regen-
erative process. Also, Western blotting results of 24 hours and 7 days groups of
AAF-treated PH groups support the model in which FLT3 is activated at late
regenerative stages. In these Western blots, we saw a decrease at FLT3 protein in
24 hours and 7 days samples which may be explained with degradation of FLT3
receptor.
When all our findings are gathered, a likely scenario would be as follows;
under normal conditions FLT3 is expressed at a constant level in liver, and it
is located in the plasma membrane in monomeric inactive form. In SH groups,
since liver regeneration is not triggered, FLT3 is seen in membrane bound inactive
monomeric form. The situation is also the same in early PH groups. In late PH
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groups, FLT3 is activated upon ligand binding and dimerization, in order to
initiate several intercellular signal transduction mechanisms which leads to cell
proliferation. Then the activated FLT3 receptors rapidly undergo internalization
and degradation, therefore FLT3 is seen in the cytoplasm in PH groups.
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5.2 Future Perspective
Our studies reveals preliminary data, that FLT3 is activated during
progenitor-cell dependent liver regeneration. For understanding the exact role
of FLT3 in this process further studies should be performed.
A protein kinase assay would provide significant data about activity of FLT3
in regeneration. Besides, kinase activity assays, other studies can provide valuable
data.
In order to confirm that cytoplasmic FLT3 staining in late AAF-treated PH
groups indicate internalization of the activated receptor, further studies should be
performed. Cytoplasmic proteins and membrane bound proteins can be isolated
separately and Western blotting can be performed on these protein samples to
investigate if FLT3 is actually seen in cytoplasm in late PH groups. Besides,
Western studies with anti-FLT3 antibody that recognizes only the phosphorylated
form of the receptor should be performed.
It is important to see if overexpression of FLT3 would affect liver regeneration.
Some studies showed that, when a plasmid carrying a gene is injected to the tail
vein of rat, the expression of the gene of interest is seen in liver 24 hours after
injection (Lui and Huang 2002; Maruyama et al, 2004). By using this method
FLT3 overexpression can be maintained in liver and whether overexpression of
FLT3 has an effect on liver regeneration can be examined.
Also, FLT3 expression can be blocked by using RNA interference technology
and its effects on liver regeneration can be observed. For achieving silencing, the
tail vein injection protocol can be adapted to this method.
In addition to studies on FLT3 receptor, investigating the expression profile
of FLT3 ligand may provide data about FLT3 activity during liver regeneration.
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